

Interferon-Gamma Inducible Protein (CXCL10) as a Predictor of Liver Fibrosis in Chronic Liver Disease

Thesis

Submitted for Partial Fulfillment of Master Degree
in Clinical and Chemical Pathology

By

Amira Abdel Azim El-saied Hussein

M.B., B.Ch., Faculty of Medicine, Ain Shams University

Under Supervision of

Prof. Dr. Hanzada Ibrahim Abdel Fattah

*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Prof. Dr. Ghada Mohamed Sadek Sabbour

*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Dr. Amira Ibrahim Hamed

*Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

**Faculty of Medicine
Ain Shams University**

٢٠١٣



Acknowledgement

*First, thanks are all direct to **ALLAH** for blessing this work until it has reached its end, as a part of generous help throughout my life.*

*It is with immense gratitude that I acknowledge the support and help of **Prof. Dr. Hanzada Ibrahim Abdel Fattah**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, this thesis would not have been possible unless her great effort, meticulous revision, and scientific guidance.*

*I am profoundly grateful to **Prof. Dr. Ghada Mohamed Sadek Sabbour**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her guidance, valuable comments and careful supervision.*

*My warmest thanks are expressed to **Dr. Amira Ibrahim Hamed**, Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her help and continuous encouragement throughout this work,*

Last but not least I would like to express my best regards and thanks to all who gave me a hand while working in this thesis and I would like to dedicate this work to my beloved family who supported me to complete it.



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا

عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية (٣٢)

List of Contents

Subject	No.	Page
List of Abbreviations		<i>i</i>
List of Figures.....		<i>ii</i>
List of Tables		<i>iv</i>
Introduction.....		١
Aim of the Work.....		٤
Review of Literature		
I – Chronic Liver Disease		٥
II - Chemokines.....		٤٩
III - CXCL-١٠/ Inducible Protein-١٠ (IP-١٠).....		٥٩
Subjects and Methods.....		٧٥
Results		٩٥
Discussion.....		١٠٩
Summary		١١٦
Recommendations		١٢٠
References		١٢١
Arabic Summary		—

List of abbreviations

Ab	: Antibody
AFP	: Alpha fetoprotein
Ag	: Antigen
AH	: Alcoholic hepatitis
AIH	: Autoimmune hepatitis
ALD	: Alcoholic liver disease
ALP	: Alkaline phosphatase
ALT	: Alanine transaminase
AMP	: Adenosine mono-phosphate
ANA	: Antinuclear antibodies
Apo-A¹	: apolipoprotein A ¹
AST	: Aspartate transaminase
AUC	: Area under curve
BCP	: Basal core promoter
BCS	: Budd–Chiari syndrome
CBC	: Complete blood count
CF	: Cystic Fibrosis
CFLD	: CF liver disease
CL	: Chemiluminescence immunoassay
CLD	: Chronic liver diseases
COPD	: Chronic Obstructive Air Way Diseases
CT	: Computerize Tomography
CTGF	: Connective tissue growth factor
ECM	: Extracellular matrix
EDHS	: Egyptian Demographic Health Survey
EIAs	: Enzyme immunoassays
ELISPOT	: Enzyme-linked immunosorbent spot
GAD	: Glutamic acid decarboxylase
GD	: Graves’ disease
GGT	: Gamma-glutamyltransferase
GSD	: Glycogen storage diseases
HBcAg	: Hepatitis B core antigen
HBeAg	: Hepatitis B e antigen

List of abbreviations (*Cont...*)

HBV	: Hepatitis B virus
HCC	: Hepatocellular carcinoma
HCV	: Hepatitis C virus
HDV	: Hepatitis D virus
HE	: Hepatic encephalopathy
HMWK	: High molecular weight kininogen
HRP	: Horseradish peroxidase
HSC	: Hepatic stellate cells
HT	: Hashimoto's thyroiditis
IFN-α	: Alfa interferon
INF-γ	: Gamma interferon
INF-β	: beta interferon
INR	: International normalization ratio
ITP	: Immune thrombocytopenia
LADA	: Latent autoimmune diabetes in adults;
MAPK	: Mitogen-activated protein kinase
MELD	: Model for end-stage liver disease
MMPs	: Metalloproteinases
MMP-ν	: gelatinase-A
MMP-ν	: Stromelysin
MMP-η	: gelatinase-B
MRI	: Magnetic resonance imaging
MS	: Multiple sclerosis
NAFLDs	: Non-alcoholic fatty liver diseases
NASH	: Non-alcoholic steatohepatitis
PBC	: Primary biliary cirrhosis
PBMNC	: Peripheral blood mononuclear cells
PC	: Precore
PICP	: Procollagen type I carboxy terminal peptide
PIIINP	: Procollagen type III amino-terminal peptide
PT	: Prothrombin time
RA	: Rheumatoid arthritis
ROC	: Receiver Operating Characteristic

List of abbreviations (*Cont...*)

ROS	: Reactive oxygen species
RT-PCR	: Reverse transcriptase polymerase chain reaction
SGA	: Small for gestational age
SGPT	: Serum glutamic pyruvate transaminase
SS	: Sjogren syndrome
TA	: Toxic adenoma
TGF-β	: Transforming growth factor- β
TNF-α	: Tumor necrosis factor alpha
WD	: Wilson disease
YKL-40	: chondrex

List of Tables

Table No.	Title No.	Page
Table (١):	Tests Used in Diagnosing Chronic Liver Disease.....	٤٠
Table (٢):	Child-Pugh Classification of Chronic Liver Disease.....	٤١
Table (٣):	Child-Pugh Score Interpretation.....	٤٢
Table (٤):	Staging of Liver Cirrhosis According to Different Classifications.....	٤٤
Table (٥):	Family of Human Chemokines and Chemokines Receptors.....	٥٢
Table (٦):	Principal Methods for Chemokine Detection and Measurement.....	٥٨
Table (٧):	Descriptive Statistics of the Studied Parameters in the Three Subject Groups.	٩٨
Table (٨):	Comparative Statistics between Control Group and CLD Patients as regards IP-١٠ using Wilcoxon's Rank Sum Test.	١٠٠
Table (٩):	Comparative Statistics between Control, Cirrhotic and Non-Cirrhotic Group as regards IP-١٠ using Kruskal Wallis Test.....	١٠٠
Table (١٠):	Between Two Group Comparison of IP-١٠ among the different Patients' Subgroups, using Wilcoxon's Rank Sum Test.	١٠٠
Table (١١):	Comparative Statistics between Non-cirrhotic Patients' Subgroups (Mild, Moderate and Severe Fibrosis) as regards IP-١٠ using Kruskal Wallis Test.	١٠١

Table (၁၃): Between Two Group Comparison of IP-၁၀ among the different Patients' Subgroups, using Wilcoxon's Rank Sum Test.	၁၀၂
--	-----

List of Tables (Cont...)

Table No.	Title No.	Page
Table (၁၃):	Comparative Statistics between Cirrhotic Group (Patients' Subgroups A, B and C) as regards IP-၁၀ using Kruskal Wallis Test.....	၁၀၃
Table (၁၄):	Between Two Group Comparison of IP-၁၀ in the different Patients' subgroups, using the Wilcoxon's Rank Sum Test.	၁၀၃
Table (၁၅):	Correlation Analysis between IP-၁၀ and Albumin, PT and INR using Spearman's Rank Correlation Coefficient.....	၁၀၄
Table (၁၆):	Diagnostic Performance of IP-၁၀ in Patients with CLD versus Control Group.	၁၀၅
Table (၁၇):	Diagnostic Performance of IP-၁၀ in Patients with Non-Cirrhotic versus Control Group.....	၁၀၆
Table (၁၈):	Diagnostic performance of IP-၁၀ in Patients with Mild or Moderate Degree of Fibrosis versus Severe.	၁၀၇
Table (၁၉):	Diagnostic Performance of IP-၁၀ in Patients with Mild Degree of Fibrosis versus Moderate or Severe.....	၁၀၈

List of Figures

Figure No.	Title No.	Page
Figure (١):	Hepatitis C Virus structure	١٠
Figure (٢):	Structure of chemokine classes.....	٥٥
Figure (٣):	IP-١٠ gene, located on human chromosome ٤	٦٠
Figure (٤):	Orthogonal views of the three IP-١٠ tetramers	٦٠
Figure (٥):	Role of IP-١٠/CXCR٣ interactions in the amplification of Th١ immune responses	٦٣
Figure (٦):	Summary of IP-١٠ expression in COPD	٧٢
Figure (٧):	Diagram showing preparation of dilution series of IP-١٠ standards for ELISA.....	٨٥
Figure (٨):	Median value of IP-١٠ in the different studied groups	٩٩
Figure (٩):	Median Value of IP-١٠ in different grades of fibrosis	١٠١
Figure (١٠):	Receiver Operating Characteristic (ROC) curve analysis showing the Diagnostic Performance of IP-١٠ in Patients with CLD versus Control Group.....	١٠٣
Figure (١١):	Receiver Operating Characteristic curve analysis showing the Diagnostic Performance of IP-١٠ in Non-Cirrhotic Group versus Control.....	١٠٥
Figure (١٢):	Receiver Operating Characteristic curve analysis showing the diagnostic performance of IP-١٠ in Mild or Moderate Degree of Fibrosis versus Severe.	١٠٦
Figure (١٣):	Receiver Operating Characteristic curve analysis showing the Diagnostic Performance of IP-١٠ in Patients with Mild Degree of Fibrosis versus Moderate or Severe.	١٠٧

Introduction

Chronic liver diseases (CLD) and its end-stages, whether benign or malignant (cirrhosis and hepatocellular carcinoma), are leading causes of morbidity and mortality worldwide with enormous socioeconomic costs (*Dooley and Dijke, 2011*).

Hepatitis C virus (HCV) infection, the most common cause of CLD, is estimated to affect 170 million individuals worldwide (2% of the world's population). The recently published Egyptian Demographic Health Survey (EDHS) in 2009 estimated an overall anti-HCV antibody prevalence of 14.7%. The number of Egyptians estimated to be chronically diseased was 9.8% (more than 5,000,000 new HCV infections occur every year) (*Millera and Abu-Raddad, 2010*).

Of all individuals exposed to the virus, the majority (50%–80%) will develop chronic infection that can result in cirrhosis and/or hepatocellular carcinoma. However, the rate of histologic progression of chronic HCV infection varies considerably among patients. Although 20%–33% of infected individuals will experience progression to cirrhosis over 20–30 years, the remainder will have mild chronic hepatitis that either does not progress or progresses very slowly. Thus, identification of patients with accelerated progression is of tremendous importance, because early treatment can prevent cirrhosis and HCC (*Zeremski et al., 2009*).

In nearly all liver diseases, progression from healthy tissue to cirrhosis is mediated by a chronic inflammatory reaction within the liver parenchyma that activates stellate cells and leads to the excess deposition of extracellular matrix proteins. This inflammatory reaction is considered to be a main predictor of disease progression across different liver disease entities. The recruitment of immune cells into the damaged liver is orchestrated by chemokines, a class of soluble immune mediators with variable chemotactic and cytokine-like functions that altered the architecture of the liver as a result of excessive scarring, development of small nodules, and changes in liver tissue (*Tacke et al., ۲۰۱۱*).

For almost all causes of chronic liver disease, assessment of fibrosis is important in estimating the prognosis of and determining the surveillance strategy for liver cancer. Moreover, assessment of fibrosis is an important parameter for decisions of antiviral therapy in viral hepatitis. Liver biopsy is still the standard and most commonly used procedure in the assessment of liver fibrosis. However, it is an invasive method associated with patient discomfort and in rare cases with serious complications (*El-Shabrawi and Isa, ۲۰۱۱*). The limitations of the procedure, including its repeatability and reproducibility, have prompted a search for non-invasive markers of hepatic fibrosis. Non-invasive procedures such as transient elastography (FibroScan) and serum biomarkers (particularly Fibrometre, Fibrotest and Hepascore) have been developed in order to avoid biopsy, however, although significant advances have been achieved in this field, none of the currently available

indices has sufficient accuracy to replace liver biopsy in the assessment of hepatic histology in patients with chronic HCV infection (*Degos et al., 2000*). The primary limitation of these indices is their inability to identify patients with intermediate stages of fibrosis (*Zeremski et al., 2009*).

CXCL10/ inducible protein-10 (IP-10) is a secreted polypeptide of 10 kDa that was first identified as an early response gene induced after gamma interferon (IFN- γ) treatment in a variety of cells. CXCL10/IP-10 can also be induced by alfa interferon (IFN- α) and beta interferon (IFN- β) as well as by lipopolysaccharide. CXCL10/IP-10 belongs to the CXC chemokine family. This chemokine is secreted by activated T cells, monocytes, endothelial cells and keratinocytes and exerts chemotactic activity towards human peripheral blood monocytes and activated T lymphocytes. Other functions of CXCL10/IP-10 include inhibition of angiogenesis, inhibition of hematopoietic progenitor cell, inhibition of tumor cell growth as well as antiviral actions (*Asensio et al., 2001*).

It has been previously reported that CXCL10 is expressed in hepatocytes and that serum CXCL10 levels are increased in patients with chronic hepatitis especially HCV infection. CXCL10 is specifically produced by hepatocytes in inflammatory areas, and may help to recruit T cells to the hepatic lesions in chronic viral hepatitis. These data have tempted researchers to study CXCL10 as a potential marker for degree of liver fibrosis (*Antonelli et al., 2009*).

Aim of the Work

The aim of this thesis is to study the clinical utility of CXCL-10 serum level as a marker for prediction of degree of fibrosis in HCV related chronic liver diseases and to correlate its levels with the results of liver biopsy in patients with no evidence of hepatic cirrhosis by ultrasonography or Child-Pugh classification in cirrhotic patients.

I – Chronic Liver Disease

A. Definition:

Chronic liver diseases (CLDs) are defined as the continuity of clinical and biochemical evidence of hepatic dysfunction for longer than six months (*Suchy, 1997*). Liver cirrhosis is the final stage of many hepatic diseases characterized by chronic cellular destruction which leads to impaired hepatic function and blood flow. The complications of liver cirrhosis are the result of hepatocellular lesion and portal hypertension, the most frequent complications are ascites, spontaneous bacterial peritonitis, hepatic encephalopathy (between 10 and 30% of patients with cirrhosis will experience an episode of overt hepatic encephalopathy) (*Lewis and Howdle, 2003*), gastro- esophageal varices, hypersplenism and hepatocellular carcinoma (HCC) (*Dioz et al., 2004*). Moreover, 30-40% of patients infected with HCV might develop at least one extrahepatic manifestation during the course of the disease (*Cacoub et al., 2000*).

B. Causes of Chronic Liver Disease:

1. Hepatitis Viruses:

a. Hepatitis B:

i. Virology:

Hepatitis B virus (HBV) was recognized as a member of hepadnaviridae family which may cause persistent infections in its natural hosts (*Howard, 1997*).